Baird reiterates Outperform rating on Owens & Minor stock, sees potential catalysts

Published 08/08/2025, 09:10
Baird reiterates Outperform rating on Owens & Minor stock, sees potential catalysts

Investing.com - Baird has reiterated an Outperform rating on Owens & Minor (NYSE:OMI) stock with a price target of $10.00, highlighting several potential catalysts for the healthcare solutions company.

The research firm believes OMI could benefit from significant cash tax advantages through the Ownership by Businesses and Beneficial Buyers Act (OBBBA), while suggesting that investor concerns over a suspected Kaiser contract loss may be exaggerated.

Baird also points to a potential sale of OMI’s Patient Health Solutions (PHS) division as a possibly accretive move for the company, while noting that the core Patient Direct business continues to demonstrate strength.

The firm’s positive outlook comes despite OMI shares having declined 52% year-to-date, significantly underperforming compared to the S&P 500’s 7.8% gain during the same period.

With the stock trading at what Baird describes as "historic lows" in terms of valuation, the firm expresses confidence that OMI offers upside potential even without the materialization of the identified catalysts.

In other recent news, Owens & Minor Inc . reported its first-quarter 2025 financial results, surpassing earnings expectations with an earnings per share (EPS) of $0.23, compared to the forecast of $0.20. However, the company’s revenues were slightly below expectations, coming in at $2.63 billion against the anticipated $2.66 billion. Additionally, Owens & Minor announced the termination of its planned acquisition of Rotech Healthcare Holdings Inc., citing regulatory challenges as the primary reason. The company paid an $80 million termination fee to Rotech Healthcare and will redeem $1 billion of notes issued in April 2025 as part of unwinding the deal. Despite this setback, Owens & Minor’s CEO, Edward A. Pesicka, remains confident in the company’s strategy, emphasizing a focus on growing their Patient Direct business and improving cash flow for deleveraging. Furthermore, at the company’s 2025 Annual Meeting of Shareholders, all nine directors up for election received substantial majority support, highlighting strong shareholder engagement. These developments reflect significant recent activities for Owens & Minor, impacting both its financial and strategic directions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.